The full data from AstraZeneca's phase 3 BaxHTN trial of baxdrostat has raised hope of an important new treatment option for people who struggle to control their blood pressure with current therapies.

With competition in the GLP-1 category increasingly cutthroat, Novo Nordisk has latched onto a real-world study that found its weight-loss drug Wegovy was better than Eli Lilly's rival Zepbound at ...

The device supports universal second-factor authentication and passwordless login, offering an alternative to proprietary ...

The ESP32-P4 is the new hotness on the microcontroller market. With RISC-V architecture and two cores running 400 MHz, to ...